General Information of Drug (ID: DMLBWT1)

Drug Name
ALRN-6924 Drug Info
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 2 [1]
Acute myeloid leukaemia 2A60 Phase 1 [1]
Myelodysplastic syndrome 2A37 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
154572842
TTD Drug ID
DMLBWT1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
p53-binding protein Mdm4 (MDM4) TT9OUDQ MDM4_HUMAN Inhibitor [2]
Ubiquitin-protein ligase E3 Mdm2 (MDM2) TT08GJW MDM2_HUMAN Antagonist [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Ubiquitin-protein ligase E3 Mdm2 (MDM2) DTT MDM2 5.162 4.909 4.174 2.907
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Haematological malignancy
ICD Disease Classification 2B33.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ubiquitin-protein ligase E3 Mdm2 (MDM2) DTT MDM2 1.19E-04 0.05 0.16
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.